ad info




CNN.com
 MAIN PAGE
 WORLD
 U.S.
 LOCAL
 POLITICS
 WEATHER
 BUSINESS
 SPORTS
 TECHNOLOGY
 SPACE
* HEALTH
 AIDS
 Aging
 Alternative
 Cancer
 Children
 Diet & Fitness
 Men
 Women
 ENTERTAINMENT
 BOOKS
 TRAVEL
 FOOD
 ARTS & STYLE
 NATURE
 IN-DEPTH
 ANALYSIS
 myCNN

 Headline News brief
 news quiz
 daily almanac

  MULTIMEDIA:
 video
 video archive
 audio
 multimedia showcase
 more services

  E-MAIL:
Subscribe to one of our news e-mail lists.
Enter your address:
Or:
Get a free e-mail account

 DISCUSSION:
 message boards
 chat
 feedback

  CNN WEB SITES:
CNN Websites
 AsiaNow
 En Español
 Em Português
 Svenska
 Norge
 Danmark
 Italian

 FASTER ACCESS:
 europe
 japan

 TIME INC. SITES:
 CNN NETWORKS:
Networks image
 more networks
 transcripts

 SITE INFO:
 help
 contents
 search
 ad info
 jobs

 WEB SERVICES:

  health > diet & fitness > story pageAIDSAlternative MedicineCancerDiet & FitnessHeartMenSeniorsWomen

FDA evidence too weak to restrict ephedra, report says

August 4, 1999
Web posted at: 12:38 p.m. EDT (1638 GMT)

Ephedra
 MESSAGE BOARDS:
Dietary Supplements
DOCTOR Q&A:
Read what doctors have to say about dietary supplements or ask your own questions.

(CNN) -- A new government report released Wednesday says the U.S. Food and Drug Administration (FDA) does not have the evidence needed to put restrictions on ephedra, a popular weight loss herb the federal agency considers dangerous.

Ephedra, also called ma huang, epitonin and sida cordifolia, contains stimulants known chemically as ephedrine. It has been promoted as a natural version of the once-popular diet drug combination fen-phen.

The FDA had proposed limits on ephedrine levels in supplements and warning labels recommending ephedra products be taken for no more than seven days.

The General Accounting Office, an investigative arm of Congress, was asked to look into the FDA's proposed restrictions after the dietary supplements industry approached Congress about the FDA's conclusions.

Since 1994, the FDA has had more than 800 reports of side effects from ephedrine, including heart palpitations, psychosis, heart attacks and strokes. But the GAO said the FDA needed to provide better evidence to support the proposed restrictions, according to a memo prepared by the House Science Committee staff.

"FDA needs to provide stronger evidence on the relationship between the intake of dietary supplements containing ephedrine alkaloids and the occurrence of adverse reactions," the GAO said.

The FDA relied heavily on so-called Adverse Events Reports without providing its usual follow-up investigation, the GAO said.

The GAO report is considered a victory for dietary supplements. Metabolife International, one of the largest distributors of ephedra in the United States, says many of the people in the FDA reports who died may have been taking the supplement, but it didn't kill them.

"There are reports in there where someone was shot and killed in a grocery story, and they happened to be taking an ephedra dietary supplement," said Metabolife's Dr. Randy Smith.

Still, University of Arkansas pharmacologist Bill Gurley said he is worried about people who take ephedra products for many weeks or who take more than the recommended dosage on the label.

"You have to realize that these things are potent cardiac stimulants, and when you are exercising and lifting heavy weights, you are already taxing your cardiovascular system, and all this does is make it work harder," said Gurley.

Gurley has analyzed approximately 20 ephedra products and found great variability in the amount of active ingredient, not only between products but often within the same brand.

"If a conventional pharmaceutical company had this kind of quality control, the FDA would shut them down in a heartbeat," Gurley said.

A 1994 federal law essentially removed dietary supplements, like herbs, from FDA control. As a result, supplements aren't subjected to the same strict clinical testing standards as prescription and most over-the-counter drugs.

Though it won't appear on the label, the FDA continues to recommend that those who are pregnant or have high blood pressure, heart conditions or neurological disorders avoid ephedra-based products.

Medical Correspondent Linda Ciampa and Reuters contributed to this report.



RELATED STORIES:
Ask the Mayo Dietitian - Supplement guide
August 4, 1999
FDA requires new diet supplement labels
March 23, 1999
FTC files complaint against 'Vitamin O' makers
March 16, 1999
NIH creates information database for dietary supplements
January 6, 1999
FTC sets guidelines aimed at more truthful dietary supplement ads
November 18, 1998
From herbs to acupuncture: Journal explores effectiveness of alternative medicine
November 10, 1998
Journal gives stern warning on unproven dietary supplements
September 17, 1998
Unregulated dietary supplements can be risky
February 22, 1998
Dieters switching to herbal fen-phen
November 7, 1997
FDA wants warning labels for some herbal supplements
February 6, 1997
Advisory panel to rule on stimulant ephedra
August 27, 1996

RELATED SITES:
U.S. Food and Drug Administration
Metabolife International
Ephedra Site
Note: Pages will open in a new browser window
External sites are not endorsed by CNN Interactive.

LATEST HEALTH STORIES:
China SARS numbers pass 5,000
Report: Form of HIV in humans by 1940
Fewer infections for back-sleeping babies
Pneumonia vaccine may help heart, too
 LATEST HEADLINES:
SEARCH CNN.com
Enter keyword(s)   go    help

Back to the top   © 2001 Cable News Network. All Rights Reserved.
Terms under which this service is provided to you.
Read our privacy guidelines.